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Abstract | Snakebite envenoming is a neglected tropical disease that kills >100,000 and 
maims >400,000 people every year. Impoverished populations living in the rural tropics 
are particularly vulnerable; snakebite envenoming perpetuates the cycle of poverty. Snake 
venoms are complex mixtures of proteins that exert a wide spectrum of toxic actions. The 
high variability in snake venom composition is responsible for a plethora of clinical 
manifestations in envenomings, ranging from local tissue damage to potentially life-
threatening systemic effects. Intravenous administration of antivenom is the only specific 
treatment to counteract envenoming. In addition, analgesics, ventilator support, fluid 
therapy, haemodialysis and antibiotic therapy are used. Novel therapeutic alternatives 
based on recombinant antibody technologies and new toxin inhibitors are being explored. 
Confronting snakebite envenoming at a global level demands the implementation of an 
integrated intervention strategy involving the WHO, the research community, antivenom 
manufacturers, regulatory agencies, national and regional health authorities, professional 
health organizations, international funding agencies, advocacy groups and civil society 
insititutions.  
 
[H1] Introduction 
Snakebite envenoming is a neglected tropical disease resulting from the injection 
of a highly specialized toxic secretion — venom — by a venomous snake into humans, 
usually under accidental circumstances. Venom is injected through the snake’s fangs, 
which are modified teeth connected via a duct to a venom gland (Fig. 1A). The 
composition of snake venoms shows high complexity and diversity1, resulting in a variable 
biochemical and toxicological profile that determines a wide range of clinical 
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manifestations. Some toxins in venoms provoke local tissue damage, often resulting in 
permanent sequelae, whereas others induce systemic effects, including neurotoxic 
manifestations (leading to, for example, respiratory paralysis), bleeding, acute kidney 
injury, rhabdomyolysis (generalized breakdown of muscle fibres), cardiotoxicity, 
autonomic hyperactivity or thrombosis. Venoms from snakes of the family Viperidae 
(viperids) cause local effects and systemic manifestations associated with bleeding, 
coagulopathies and hypovolaemic shock2. Venoms from snakes of the family Elapidae 
(elapids) predominantly induce neurotoxic manifestations, such as neuromuscular 
paralysis2. 
The superfamily Colubroidea — or advanced snakes — consists of >2,500 species 
with a wide geographical distribution and an extended evolutionary history. The 
superfamily includes all venomous snakes classified in the taxon Caenophidia, order 
Squamata, suborder Serpentes. The most dangerous species are classified within the 
families Viperidae (true vipers and pit vipers) and Elapidae (elapids, for example, cobras, 
kraits, mambas and sea snakes) (Fig. 1b–i)3,4. Additionally, some species of the families 
Lamprophiidae (lamprophiids; subfamily Atractaspidinae, for example burrowing asps or 
stiletto snakes) and several subfamilies of non-front-fanged colubroid snakes are also 
capable of inflicting envenomings2.  
Because snakes are ectothermic, they are abundant in warmer climates, restricting 
the hyperendemic regions for snakebites mostly to tropical countries of the developing 
world (especially to Africa, Asia, Latin America and Oceania)5–7. In those countries, contact 
between snakes and humans is relatively common particularly in the rainy season when 
human agricultural activity coincides with the snakes’ breeding season. Epidemiological 
evidence gathered from hospital records underscores the high burden of snakebite 
envenomings, which is considerable in terms of mortality and sequelae5,8. Evidence from 
community-based surveys in some countries suggests that the actual toll is even higher 
than estimates from hospital-based statistics (see for example6). By contrast, inhabitants 
of higher-income countries of North America and especially Europe have far less exposure 
to venomous snakes and are generally unaware of the scale of the public health problem 
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posed by snakebites elsewhere. Consequently, snakebite envenoming have historically 
received little attention from funding bodies, public health authorities, the pharmaceutical 
industry and health advocacy groups, thereby impairing the development of effective 
interventions to reduce the social impact of snakebites9,10. 
This Primer summarizes the main issues of snakebite envenoming, including the 
epidemiology, the composition of snake venoms, and the pathophysiology, clinical 
manifestations, prevention and clinical management of snakebite envenomings. The 
global efforts being carried out for reducing the impact of this pathology are described, 
together with future trends to better understand and confront this neglected tropical 
disease.  
[H1] Epidemiology  
Snakebite envenoming is a major public health problem in the developing world 
(Fig. 2). It is an important cause of morbidity and mortality especially in the impoverished 
areas of the warmer tropics and subtropics, such as sub-Saharan Africa, South to South-
East Asia, Papua New Guinea and Latin America6,7,11. Snakebite envenoming occurs in at 
least 1.8–2.7 million people worldwide per year, with combined upper estimates of 
mortality ranging from 81,410 to 137,880 (Refs5,12). At least 46,000 of these deaths occur 
in India alone6. In sub-Saharan Africa, where data are fragmented, mortality estimates 
range from 7,000 to 32,000 deaths per year5,7,12, but are likely be underestimated given 
that, in West Africa alone, annual mortality has been estimated at 3,557–5,450 (Ref.13).  
Snakebites disproportionately affect lower socioeconomic segments of society, 
people with poorly constructed housing and those with limited access to education and 
health care11,13. Countries with low gross domestic product, Human Development Index (a 
composite statistic of life expectancy, education and income) and low healthcare 
expenditure are the most affected11. The disease pushes poor people further into poverty 
by virtue of high treatment costs, enforced borrowing and loss of income11. Indeed, bites 
and fatalities are most common in people 10–40 years of age, comprising the most 
productive members of rural communities14. Those <5 years of age experience higher 
case-fatality15. In India, the proportion of all deaths from snakebites was highest at ages 
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5–14 years6. Children are exposed while helping in agricultural duties, playing or placing 
their hands in rodents’ burrows. 
Snakebite envenoming is an occupational and environmental disease of the young 
and agricultural workers. The specific populations at risk differ between countries. For 
example, tea pickers are at risk in southern India and Sri Lanka, rubber tappers in Liberia, 
Thailand, Malaysia, other South East Asian countries and Brazil, and sugar cane workers in 
South Africa, Saint Lucia and Martinique16–19. In Myanmar, snakebite envenoming is the 
5th leading cause of death, particularly affecting rice paddy farmers20. Fishermen using 
hand nets and lines in warmer tropical seas are also at risk, as are families of agricultural 
workers. Pregnant women are a highly vulnerable group, and snakebite has been 
recognized in Nigeria and Sri Lanka as an important cause of abortion and antepartum 
haemorrhage, as well as maternal and fetal loss21.  
Snakebite is also an environmental hazard of indigenous nomadic peoples, hunter-
gatherers, tribes, firewood collectors and indigents (extremely poor individuals). This risk 
has been documented in South America19, Africa (for example, the Hadza hunter-
gatherers of Tanzania, the African Bushmen of the Kalahari desert or Southern Africa, the 
nomadic Fulani and Turkana pastoralists (sheep or cattle farmers) of the savanna in West 
Africa and Kenya)22, India and Sri Lanka. Envenoming has been an important cause of 
death among the indigenous communities of Australia, of the coastal lowlands of New 
Guinea23 and of the Amazon (Yanomami and Waorani ethnic groups)18,19.  
A proportion of individuals develop chronic morbidity, disability and psychological 
sequelae following snakebite envenoming, including amputations, post-traumatic stress 
disorder, blindness, maternal and fetal loss, contractures (permanent shortening of a 
muscle or joint often leading to deformity or rigidity), chronic infections and malignant 
ulcers7,21,24–26. At least 6,000 amputations owing to snake bites occur annually in sub-
Saharan Africa alone7. Even when chronic disability is not factored in, the burden of 
premature death alone as a consequence of snakebite envenoming in India is estimated at 
2.97 million disability-adjusted life years, whereas the global burden is conservatively 
estimated at 6.07 million disability-adjusted life years6,12,13. This is more than twice the 
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estimate suggested for contributions grouped under ‘venomous animal contact’ in the 
Global Burden of Disease study27, underscoring a notorious underreporting of snakebites 
in official records. When both premature deaths and disability from snakebites are 
factored for 16 countries in West Africa, the combined burden surpasses the worldwide 
burdens for other neglected tropical diseases such as buruli ulcer, echinococcosis, leprosy, 
trachoma, yaws, yellow fever and podoconiosis. The burden of snakebites in sub-Saharan 
Africa is also higher than the burden of trypanosomiasis, leishmaniasis and 
onchocerciasis13.  
 
[H1] Mechanisms/pathophysiology 
[H2] Snake venom  
[H3] Evolution of snake venoms. Venoms are used for predatory and defensive purposes 
and have evolved independently in a wide phylogenetic range of organisms, including 
snakes, spiders, scorpions and jellyfish28. Venom represents a trophic adaptive trait crucial 
for the foraging success of venomous snakes, and as such has had key roles in the 
organismal ecology and evolution of advanced snakes29. As a result of rapid evolution 
under Darwinian positive selection, venoms comprise protein mixtures of varying 
complexity that act individually or as an integrated phenotype to injure or kill the prey or 
accidental victim. Despite being traits of moderate genetic complexity in terms of number 
of genes that encode toxins, within-species and between-species venom variability seems 
to be a common feature at all taxonomic levels30. The mechanisms that generated such 
biodiversity remain largely elusive, although genomic reorganizations and other 
alterations in genes encoding toxins and toxin expression patterns might be involved31–35. 
Like eyes, fins and wings, which have evolved independently in a number of different 
lineages, animal venoms have also been shaped by convergent structural and functional 
evolution36. Convergent evolution has repeatedly selected a restricted set of genes 
encoding proteins containing specific structural motifs as templates for 
neofunctionalization (the process by which a gene acquires a new function after a gene 
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duplication event) as venom toxins in different taxa37. Gene duplication, evolutionary 
divergence and post-translational quaternary associations in homomer or and heteromer 
multiprotein complexes38 add to the complexity of snake venoms, by generating mixtures 
of proteins belonging to a handful of multigenic protein families; some of these protein 
families exhibit remarkable intrafamily variability39.  
  Unveiling the spatial and temporal distribution of variations in venom composition 
within and between species is essential to understand the evolutionary processes and the 
ecological constraints that molded snake venoms to their present-day variability and to 
define the phylogeographic boundaries of species. Insights into the selective pressures 
that resulted in local adaptation and species-level divergence in venoms can shed light on 
the mutual relationship between evolutionary and clinical toxinology: toxins bearing the 
highest prey incapacitation activity are often also the most medically important molecules 
in the context of a human envenoming. Thus, identifying the molecular basis of venomous 
snake adaptation to their natural ecosystems may assist in the identification of those 
toxins that must be neutralized to reverse the effects of venom, thereby guiding the 
rational development of next-generation snakebite therapeutics40.  
 
[H3] Analysis of snake venom composition. The growing interest in different aspects of 
venom biology has catalysed the development of ‘omics’ methodologies aimed at the 
qualitative and quantitative characterization of venom toxins, including the proteomics of 
venoms (that is, venomics; Box 1). In particular, the combination of next-generation 
transcriptomics41,42 and proteomics workflows has demonstrated unparalleled capabilities 
for venom characterization in unprecedented detail. Figure 3 summarizes the relative 
distribution of the main types of toxic components in viperid and elapid venoms. 
 A straightforward translational application of the body of knowledge gained 
through venomics is the analysis of the immune reactivity of antivenoms against venoms, 
a field coined ‘antivenomics’ (Fig. 4). Antivenomics is a proteomics-based protocol to 
quantify the extent of cross-reactivity of antivenoms against homologous and 
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heterologous venoms43. The combination of antivenomics and in vivo neutralization tests 
constitute a powerful toolbox for evaluating the preclinical efficacy of an antivenom44. 
 
[H2] Mechanism of action  
Snakes inject their venoms through a specialized delivery system, which includes a 
set of fangs located in the frontal region of the maxillary bones in viperids (Fig. 1a), elapids 
and lamprophiids, whereas fangs have a posterior location in non-front-fanged colubroids. 
Depending on the size of the fangs, venom is injected either subcutaneously or 
intramuscularly. Once delivered, some venom toxins exert local pathological effects in 
neighboring tissues, whereas others are distributed systemically through the lymphatic 
system and blood vessels, enabling toxins to act at various organs2. Activities of main toxin 
families are shown in Box 2, whereas the potential consequences of snakebite 
envenoming are shown in Figure 5.  
 
[H3] Local tissue damage. Most viperid and some elapid venoms induce local tissue 
damage. Myonecrosis is primarily due to the action of myotoxic phospholipases A2 (PLA2s) 
present in these venoms, which bind and disrupt the integrity of the plasma membrane of 
muscle fibres45,46. For some PLA2s, disruption of plasma membranes is secondary to 
hydrolysis of membrane phospholipids, whereas in the case of catalytically-inactive PLA2 
homologues, sarcolemmal damage occurs through hydrophobic interactions47. Calcium 
influx into the cytosol occurs following membrane perturbation, causing myofilament 
hypercontraction, mitochondrial dysfunction and other degenerative events, leading to 
irreversible muscle cell damage46,47. Small basic myotoxic peptides present in some 
rattlesnake venoms also induce muscle contracture and can cause necrosis2. Muscle fibers 
are also affected by ischaemia resulting from vascular alterations and from increased 
pressure in muscles as a consequence of oedema48. Skeletal muscle regeneration requires 
the removal of necrotic debris by phagocytic cells, and depends on an intact blood supply 
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and innervation to be successful. In viperid venoms, which affect muscle fibres and 
damage the vasculature and nerves, skeletal muscle regeneration is impaired, often 
resulting in permanent sequelae48,49.  
In addition to myonecrosis, blood vessel integrity is also affected. Snake venom 
metalloproteinases (SVMPs) in viperid venoms hydrolyse key components of the 
basement membrane of capillaries, particularly type IV collagen, causing the weakening of 
the mechanical stability of microvessels. As a consequence, the haemodynamic 
biophysical forces operating in the circulation cause distension and, eventually, disruption 
of the capillary wall, resulting in extravasation50. SVMP-induced microvascular damage can 
also be a consequence of the disruption of endothelial cell-cell adhesions51. SVMPs and 
hyaluronidases hydrolyse extracellular matrix components, including various types of 
collagens, hyaluronic acid and proteoglycans, affecting the structure and function of not 
only microvessels but also other tissue components, thereby playing a part in venom-
induced local tissue damage52.  
SVMPs also induce skin damage by degrading the dermal-epidermal interphase, 
with the consequent formation of blisters53. Some cobra (Naja sp., family Elapidae) 
venoms induce extensive cutaneous necrosis owing to the action of cytotoxins of the 
three-finger toxin family54, so named for having a common structure of three loops 
extending from a central core, which destabilize plasma membranes of various cell types 
in different tissues through a non-enzymatic mechanism55. Locally-acting toxins (that is, 
PLA2s and SVMPs) also affect intramuscular nerves
49 and other vascular components such 
as lymphatic vessels, arterioles and venules56. 
An extensive local inflammatory process develops in envenomed tissue, with the 
synthesis and release of eicosanoids, nitric oxide, bradykinin, complement anaphylatoxins, 
histamine, cytokines, the activation of resident macrophages and other cell types, and the 
recruitment of leucocytes57. This inflammatory milieu induces an increased vascular 
permeability with formation of an exudate that, in addition to plasma proteins, contains 
intracellular and extracellular protein fragments, chemokines, cytokines and damage-
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associated molecular patterns (DAMPs), which are likely to potentiate the inflammation 
and, possibly, contribute to further tissue damage58. 
Some mediators also induce pain57. Catalytically-inactive PLA2 homologues excite 
pain-related sensory neurons via ATP release and activation of purinergic receptors59.  
 
[H3] Neurotoxicity. Snake venoms of most elapid species, and of some viperid species, 
contain neurotoxins that induce a descending flaccid neuromuscular paralysis, which can 
involve the life-threatening blockade of bulbar (muscles of the mouth and throat 
responsible for speech and swallowing) and respiratory muscles. Two main types of 
neurotoxins are found in snake venoms: α-neurotoxins and β-neurotoxins.  
α-Neurotoxins belong to the three-finger toxin family and exert their action post-
synaptically at neuromuscular junctions60. They bind with high affinity to the cholinergic 
receptor at the motor end plate in muscle fibres, thereby inhibiting the binding of 
acetylcholine and provoking flaccid paralysis60.  
By contrast, β-neurotoxins are typically PLA2s that act at the presynaptic nerve 
terminus of neuromuscular junctions61. For example, the receptor for β-bungarotoxin, 
from the krait Bungarus multicinctus (family Elapidae), is the voltage-gated potassium 
channel62. Upon binding to their targets, neurotoxic PLA2s induce enzymatic hydrolysis of 
phospholipids at the nerve terminal plasma membrane, which causes neurotoxicity63. 
Indeed, the generation of lysophospholipids and fatty acids in the membrane cause 
biophysical changes that lead to the fusion of synaptic vesicles to the membrane and the 
exocytosis of the ready-to-release pool of vesicles46. Furthermore, membrane 
permeability to ions is increased, with the consequent depolarization and influx of 
calcium, resulting in exocytosis of the reserve pool of vesicles61. Consequently, presynaptic 
vesicles are depleted, and intracellular degenerative events ensue, including 
mitochondrial alterations, ending up in the destruction of nerve terminals64,65. These 
events explain the prolonged and severe paralysis observed in patients. Some neurotoxic 
11 
 
 
PLA2s can also act intracellurlarly after entering the cytosol by endocytosis or through the 
damaged plasma membrane62. Within the nerve terminus, PLA2s cause further 
degenerative events in mitochondria66. 
Other neurotoxins are dendrotoxins and fasciculins, present in the venoms of the 
African elapids mambas (Dendroaspis sp.; family Elapidae). Dendrotoxins block voltage-
gated potassium channels at the presynaptic nerve terminal67. Fasciculins, which also 
belong to the three-finger toxin family, are inhibitors of acetylcholinesterase68. Their 
combined action results in excitatory effects and fasciculations (involuntary muscle 
contraction). Some cysteine-rich secretory proteins (CRISPs) in venoms induce paralysis of 
smooth muscle2. 
[H3] Cardiovascular and haemostatic disturbances. Systemic haemorrhage occurs in 
envenomings by viperids and by some species of non-front-fanged colubroids, and can 
also develop in envenomings by Australian elapids. In viperid venoms, the main toxins 
responsible for systemic haemorrhage are SVMPs, especially those of the PIII class. These 
toxins have a multi-domain structure containing exosites (molecular sites distinct from the 
active catalytic site that serve as secondary binding sites) that enable them to target the 
microvasculature50,69. Bleeding can occur in different organs with several 
pathophysiological consequences. For example, intracranial haemorrhage has been 
described in envenomings, causing ischaemia and stroke, and leading to neurological 
sequelae70,71. The mechanism of action of systemically-acting haemorrhagic SVMPs is 
likely to be similar to that described for local haemorrhage, that is, cleavage of key 
substrates at the basement membrane of capillaries and at cell–cell junctions, resulting in 
the mechanical weakening of the microvessel wall and extravasation50,51.  
Snake venoms affect haemostasis in various ways. Many viperid venoms, and some 
elapid and non-front-fanged colubroid venoms, contain enzymes that promote 
coagulation; these enzymes are either SVMPs or snake venom serine proteinases that act 
in the coagulation cascade, such as thrombin-like enzymes or activators of coagulation 
factor V, factor X or prothrombin72,73. Some venom enzymes also hydrolyse fibrinogen and 
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fibrin73. SVMPs also release tissue factor74 and affect endothelial function in various ways. 
Although these procoagulant components can cause intravascular coagulation, in the 
majority of cases they induce a consumption coagulopathy, resulting in defibrinogenation 
and incoagulability that are reflected in the alteration of blood clotting tests70. This 
condition may contribute to systemic bleeding, especially in venoms containing 
haemorrhagic toxins that disrupt the integrity of blood vessels2,70. Some Australian elapid 
venoms, which lack haemorrhagic SVMPs but cause coagulopathy secondary to the action 
of serine proteinase prothrombin activators, often induce systemic bleeding70.  
Many snake venoms affect platelets. SVMP-mediated microvascular damage and C-
type lectin-like proteins contribute to the drop in platelet numbers75. Moreover, 
disintegrins, C-type lectin-like proteins, snake venom serine proteinases and some SVMPs 
impair platelet aggregation by blocking platelet receptors or by interacting with von 
Willebrand factor73,76,77. Thrombocytopenia has been associated with an increased risk of 
systemic bleeding in envenomings by haemorrhagic venoms. By contrast, the venoms of 
two endemic Caribbean viperid species induce severe thrombosis leading to infarcts in 
lungs, brain and heart, despite not being directly procoagulant78. Thrombosis is likely 
dependent on SVMP-induced systemic endothelial dysfunction. Acute pituitary 
insufficiency secondary to thrombi formation and focal haemorrhage in the anterior 
pituitary glands occurs in bites by some viperids79.  
Venom-induced systemic bleeding is one of the leading causes of the 
haemodynamic disturbances experienced by patients envenomed by viperids, which may 
progress into cardiovascular shock2. In these envenomings, hypovolaemia also results 
from an increase in vascular permeability, including systemic plasma leakage. This effect is 
induced by snake venom serine proteinases that release bradykinin and also by the action 
of a plethora of vasoactive endogenous inflammatory mediators. In addition, viperid 
venoms contain bradykinin-potentiating peptides, some of which inhibit the angiotensin-
converting enzyme and contribute to haemodynamic alterations80.  
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 Hyponatremia, possibly caused by venom natriuretic factor, may play a part in 
cardiovascular disturbances in some envenomings81. A direct cardiotoxic effect might also 
add to the multifactorial setting of haemodynamic disturbances; sarafotoxins are 
responsible for cardiotoxicity in atractaspid venoms2. Sepsis has been described in 
snakebite victims as a consequence of infection, further contributing to cardiovascular 
dysfunction and shock.  
[H3] Acute kidney injury. Some viperid and some elapid snakebite envenomings can lead 
to acute kidney injury82. Depending on the type of venom, the following mechanisms have 
been associated with the pathogenesis of renal damage: ischaemia secondary to 
decreased renal blood flow resulting from the haemodynamic alterations caused by 
systemic bleeding and vascular leakage; proteolytic degradation of the glomerular 
basement membrane by SVMPs; deposition of microthrombi in the renal microvasculature 
(that is, thrombotic microangiopathy), which might also cause haemolysis; direct cytotoxic 
action of venom components, such as cytotoxic PLA2s, in renal tubular cells; in the cases of 
venoms inducing systemic myotoxicity, accumulation of large amounts of myoglobin in 
renal tubules, with consequent toxicity82,83. 
[H3] Rhabdomyolysis. Envenomings by sea snakes, some Australian terrestrial elapids, 
and some viperid species are associated with systemic myotoxicity, that is, 
rhabdomyolysis2. This effect is due to the action of myotoxic PLA2s at the systemic level 
owing to the binding of these toxins to receptors in muscle fibers. Myotoxins disrupt the 
integrity of the plasma membrane of muscle cells, as described for locally-acting 
myotoxins, causing calcium influx and cellular degeneration47. Thus, large amounts of 
muscle cytosolic proteins, such as creatine kinase and myoglobin, are released. Deposition 
of myoglobin in the renal tubules may contribute to acute kidney injury82.  
[H1] Diagnosis, screening and prevention  
Snakebites are emergencies that are clinically challenging owing to their potentially 
rapid lethality. Uncertainties about species identity and the quantity of venom injected 
and its composition, which can vary with the snake’s age and, within species, throughout 
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its geographical range, complicate decision making84. Most snakebites are managed by 
nurses or health assistants in district and rural hospitals, clinics, dispensaries and health 
posts. In some cases, referral to a provincial tertiary hospital with specialists, intensive 
care units and laboratories might be possible. 
[H2] Clinical presentation 
Victims of snakebite envenoming present with local and systemic symptoms of 
envenoming, as well as anxiety and symptoms associated with the treatment they 
received before arriving in hospital or health care post. Fear can cause misleading 
symptoms such as vomiting, sweating, tachycardia, acroparaesthesiae (abnormal 
sensation in extremities), carpopedal spasm (tetany causing painful cramps of hands, 
wrists and feet), tachypnoea and hyperventilation leading to syncope, and functional 
neurological disorders. Widely practiced traditional first-aid treatments for snakebites 
include tight bands or tourniquets85, local incisions, ingestion of emetic herbs or topical 
application of herbs, or application of ice, suction, fire or electric shocks at the site of bite. 
Not only is the effectiveness of these traditional treatments not proven, but they can 
result in treatment-associated comorbidities even in the absence of envenoming such as a 
painful, swollen, ischaemic or even gangrenous limb, bleeding or infections.  
The specific clinical manifestations associated with bites of viperids, elapids or non-
front-fanged colubroid snakes are described below.  
[H3] Viperids. The classic syndrome associated with bites from viperids (including 
Viperinae (true Old World vipers and adders) and Crotalinae (Asian pit-vipers, mamushis, 
habus and New World rattlesnakes, moccasins, bushmasters and lanceheads)) consists of 
local and systemic effects. Local effects in the bitten limb include immediate radiating 
pain; rapidly-extending tender swelling with hot inflammatory erythema; signs of 
lymphangitis (inflammation of the lymph vessels presenting with red lines on the skin), 
which usually becomes evident within 2 hours of the bite; prolonged bleeding from fang 
puncture wounds; bullae (blistering); ecchymosis (bruising); tender regional lymph node 
enlargement; superficial soft tissue and muscle necrosis and secondary infection (cellulitis 
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or abscess) (Fig. 6a,b)19,86,87. Systemic effects include early syncope and collapse with 
transient loss of vision and consciousness; hypotension and shock; cardiac 
tachyarrhythmia or bradyarrhythmia; severe bleeding diathesis, spontaneous systemic 
bleeding from nose, gums (Fig. 6c), respiratory, gastrointestinal and genitourinary tracts 
and sites of recent trauma or healing wounds, and subarachnoid, cerebral, and 
antepartum or postpartum haemorrhages; and abortion and fetal death19,86,87.  
Variant syndromes consist of symptoms in addition to those described above and are 
associated with envenoming by particular species. These symptoms include early 
‘anaphylactic’ (autonomic) symptoms (for example, urticaria, angioedema, shock, 
sweating, vomiting and diarrhoea), acute kidney injury, generalized increase in capillary 
permeability, for example chemosis (Fig. 6d), acute or chronic pituitary failure, 
neuromyotoxicity and in situ arterial thrombosis (causing ischaemic infarcts in brain, 
kidney, lungs, heart or elsewhere). Envenoming by some rattlesnakes (Crotalus sp.) causes 
neuromyotoxic symptoms, characterized by fasciculations in North America and elapid-
like descending paralysis with rhabdomyolysis and acute kidney injury in South America19. 
Envenoming by bushmasters (Lachesis sp.) can cause dramatic early autonomic symptoms, 
sometimes with vaso-vagal features, and severe local envenoming19. A review of the 
species causing these symptoms is beyond the scope of this Primer, but additional 
information is provided in Supplementary file S1 and reviewed elsewhere19,86,87.  
[H3] Elapids. Bites of elapid snakes (including cobras, kraits, mambas, coral snakes, 
Australian and Oceanic venomous snakes, and seasnakes) are associated with the classic 
neurotoxic syndrome, which is characterized by flaccid paralysis that is first evident as 
bilateral ptosis and external ophthalmoplegia (Fig. 6e,f) sometimes with dilated pupils. 
Drowsiness is occasionally mentioned but snake venom toxins are not thought to cross the 
blood–brain barrier, so this finding is difficult to explain. Paralysis descends to involve 
muscles innervated by lower cranial nerves and neck flexors, as well as bulbar, respiratory, 
trunk and limb muscles. Other symptoms are pooling of secretions in the pharynx, loss of 
the gag reflex, dyspnoea, declining ventilatory capacity, paradoxical abdominal 
respiration, use of accessory muscles and cyanosis, which are ominous signs of impending 
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bulbar and respiratory paralysis. Paralysis is sometimes reversible following treatment 
with acethylcholinesterase inhibitors or specific antivenoms, and recovers over time in all 
cases, provided that respiration is adequately supported19,23,86–89. Local symptoms include 
absent-to-moderate pain, paraesthesiae and local swelling, without blistering or necrosis.  
Variant syndromes consist of severe local envenoming with immediate radiating 
pain and rapidly extending tender swelling, blistering, superficial, patchy (presence of ‘skip 
lesions’) soft tissue necrosis (Fig. 6g) and secondary infection, tender regional lymph node 
enlargement, autonomic overactivity and fasciculations, severe abdominal pain 
resembling renal or biliary colic (which gradually increases in intensity), excruciating pain 
radiating up the bitten limb and acute kidney injury associated with rhabdomyolysis, 
hyponatraemia, spontaneous bleeding and coagulopathy, and microangiopathic 
haemolysis. Venom spat into the eyes by spitting elapids can lead to ophtalmia, resulting 
in intensely painful chemical conjunctivitis with lacrimation and swelling of eyelids, risk of 
corneal ulceration, anterior uveitis, and secondary infection leading to permanent 
blindness (Supplementary file S1) 19,86,87.  
[H3] Non-front-fanged colubroids. Bites from non-front-fanged colubroid snakes 
(including the African boomslang (Dispholidus typus), vine snakes (Thelotornis sp.), Asian 
keel-backs (Rhabdophis sp.) and South American racers (Philodryas sp.)) are associated 
with slowly or late evolving ecchymoses, systemic bleeding, coagulopathy and acute 
kidney injury with minimal local envenoming. There have been fatalities from envenoming 
by the African and Asian species, but South American non-front-fanged colubroid snakes 
seem to be less dangerous. Mild local envenoming can be caused by bites of many 
colubroid species, some of which are kept as pets in the West (for example, hognose 
snakes Heterodon sp.) (Supplementary file S1)90,91.  
[H3] Clinical time course. After bites by vipers (family Viperidae) and some cobras (family 
Elapidae), local swelling is usually detectable within 2–4 hours and can extend rapidly to 
reach its peak on the second or third day. Blistering appears within 2–12 hours and tissue 
necrosis becomes obvious within 1 day of the bite. Sloughing of necrotic tissue and 
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secondary infections including osteomyelitis (infection of underlying bone) develop during 
subsequent weeks or month. Complete resolution of swelling and restoration of normal 
function in the bitten limb may take weeks. Systemic envenoming may be heralded by 
vomiting or syncope within minutes of the bite. Coagulopathy and bleeding develop 
within a few hours and can persist for ≥2 weeks in untreated patients. Neurotoxic signs 
can progress to generalized flaccid paralysis and respiratory arrest within 30 minutes to a 
few hours. Patients with neurotoxic envenoming usually recover within a few days with 
assisted ventilation, but some may need respiratory support for as long as 10 weeks19,86,87.  
[H2] Diagnosis 
To deduce the nature and severity of envenoming, a sequential clinical history of 
symptoms must be obtained and signs of envenoming rapidly elicited (Box 3), so that 
appropriate, urgent, life-saving treatment can be given. Rapid clinical assessment must 
include vital signs, measurement of postural blood pressure to exclude hypovolaemia, 
formal testing for ptosis and signs of more advanced paralysis especially causing 
respiratory failure, and examination for spontaneous systemic bleeding.  
 Patients usually know that they have been bitten, except those who suffer 
painless nocturnal bites by kraits (Bungarus, Family Elapidae) while asleep92,93. Differential 
diagnoses of snakebites include bites by arthropods (for example, spiders), lizards, rodents 
or fish, stings (for example, by hymenopteran, scorpions or centipedes), or punctures by 
plant spines or thorns, nails, splinters or other sharp objects. Definite snakebites that 
result in negligible or no symptoms may have been ‘dry bites’ (transcutaneous bites 
without envenoming94) inflicted by venomous snakes or bites by non-venomous species. If 
the dead snake, or a photograph of it, is available, an expert herpetologist can identify the 
species. Otherwise, descriptions by victims or bystanders can be helpful, supported by 
recognition of evolving characteristic patterns (syndromes) of symptoms95 and aided by 
biochemical measurements and imaging. 
[H3] Laboratory and other investigations. Laboratory investigations can help to identify 
systemic envenoming and aid the management of snake bites. Peripheral neutrophil 
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leucocytosis, indicating a general inflammatory response, confirms systemic envenoming. 
Low haematocrit (volume percentage of red blood cells in blood) reflects severe 
haemorrhage, whereas high haematocrit reflects haemoconcentration from leakage of 
plasma into the tissues as a result of increased capillary permeability. Severe 
thrombocytopenia is associated with severe bleeding diathesis and sometimes with 
microangiopathic haemolysis, diagnosed by the presence of schistocytes in a blood film, 
causing acute kidney injury. Incoagulable blood is a cardinal sign of systemic envenoming 
by viperids, Australian and Oceanic elapids and non-front-fanged colubroid snakes. The 
simple 20 minute whole blood clotting test (20WBCT) involves placing a few millilitres of 
venous blood in a new, clean, dry, glass vessel, leaving it undisturbed at room 
temperature for 20 minutes, and then tipping it once to see if it has clotted96,97. Lack of 
clotting indicates severe consumption coagulopathy or an anticoagulant venom87. 
Laboratory tests such as prothrombin and activated partial thromboplastin times, fibrin 
degradation products and D-dimer are more sensitive indices of disseminated 
intravascular coagulation and fibrinolysis. Levels of creatine kinase of >10,000 units per 
litre indicate severe rhabdomyolysis. Blood urea or serum creatinine and potassium 
concentrations should be measured in patients at risk of acute kidney injury. Urine should 
be tested on admission for the presence of haemoglobin, myoglobin, blood and protein.  
Electrocardiographic abnormalities include sinus bradycardia, ST–T changes, and 
varying degrees of atrioventricular block or evidence of myocardial ischaemia. Myocardial 
infarction can occur secondary to shock in patients with pre-existing coronary artery 
disease. Echocardiography will detect pericardial effusion and myocardial dysfunction and 
bleeding into the pleural and peritoneal cavities. Wound ultrasonography has also been 
advocated to detect local bleeding98. CT and MRI is increasingly available for assessing 
intracranial haemorrhages and infarcts.  
[H3] Detection of venom. Detection and quantitation of venom antigens in body fluids of 
snakebite victims, using enzyme immunoassays99–102 provides retrospective confirmation 
of species diagnosis, predicts prognosis and is one measure of the effectiveness of 
antivenom (also known as antivenin, antivenene, anti-snake-bite or anti-snake venom 
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serum) treatment. High concentrations of venom antigen (that is, from wound swabs or 
wound aspirates) can be detected within 15–30 minutes, but commercial venom 
detection kits are available only in Australia (produced by Seqirus, Parkville. Australia)103. 
Venom detection kits are highly sensitive but insufficiently specific to distinguish between 
venoms of closely related species. Detection of venom in a wound swab does not prove 
that the patient has been envenomed and is not, on its own, an indication for antivenom 
treatment. For retrospective species diagnosis, including forensic cases, tissue around the 
fang punctures, wound and blister aspirate, serum and urine should be stored for enzyme 
immunoassays. Detection of venom gland mRNA by reverse-transcription PCR104 or snake-
derived DNA in bite wound swabs105 are being developed as highly specific methods for 
determining the identity of the biting species. 
[H2] Prevention  
The most effective method of preventing snakebites (Box 4) is through education 
directed at high-risk communities and designed and driven from within those 
communities86,87. A full range of media should be employed, including radio, TV, mobile 
phone apps, social media, posters, puppet and drama performances and village-based 
public meetings. Awareness of snakebite envenoming must be increased together with 
advice on safer walking, working106 and sleeping107. Transport of bite victims to clinics 
where they can receive medical care can be improved, even in areas that are inaccessible 
to conventional ambulances, for example, using boats or volunteer village-based 
motorcyclists108. Wasting time by visiting traditional therapists should be tactfully but 
firmly discouraged. 
 
[H1] Management 
[H2] First-aid 
Immediate first-aid after a bite should be done by the victim or bystanders. 
Important elements are reassurance, immobilization of the whole body, especially the 
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bitten limb (to reduce dissemination of venom through veins and lymphatic system), 
removal of rings and tight objects around the bitten limb and application of a pressure-
pad or pressure-bandage over the bite wound109,110. The patient must be transported 
rapidly and preferably passively to the nearest place affording medical care. Pain should 
be controlled using paracetamol (acetaminophen) or opioids, but not aspirin or NSAIDs 
because of the risk of exaggerating bleeding problems. Minimizing the risk of fatal shock 
and upper respiratory obstruction (through bulbar paralysis or fluid aspiration) during 
transit is achieved by placing the victim in the recovery position and inserting an 
oropharyngeal airway (a tube to maintain the airway). Ineffective and damaging 
traditional treatments such as incisions, suction and tight tourniquets must be 
discouraged. In suspected cases of neurotoxic envenoming by cobras, death adders 
(Acanthophis sp.), some Latin American coral snakes (Micrurus sp.), and other elapids 
whose venoms act mainly on postsynaptic receptors of the neuromuscular junction, 
administration of atropine and neostigmine (an acetylcholinesterase inhibitor) to improve 
neuromuscular transmission has been suggested as first-aid111.  
 
[H2] Hospital management 
Patients who claim to have been bitten by a snake should be admitted for a 
minimum of 24 hours. They should be clinically assessed as described above. An 
intravenous line and necessary resources for immediate resuscitation should be in place 
before an in situ compression bandage or tourniquet is removed as this may precipitate 
dramatic deterioration112. In patients who are breathless and centrally cyanosed (lips, 
tongue and mucosae are blue because the blood is poorly oxygenated), the airway should 
be restored and oxygen given by any possible means. If the patient is in shock, the foot of 
the bed should be raised immediately, and intravenous fluid infused. Pain is variable but 
might be very severe and should be treated appropriately, as described above. 
Patients who initially present without evidence of envenoming can deteriorate 
rapidly and unpredictably over minutes or hours. Published severity scores usually based 
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on arbitrary criteria are, therefore, inherently unreliable or even potentially dangerous. 
However, several studies have shown that admission levels of venom antigenaemia 
(concentration of venom antigens in serum or plasma detected by enzyme immunoassays) 
were of prognostic value113,114. Snakebite victims should be carefully observed and their 
blood pressure, pulse rate, level of consciousness, presence or absence of ptosis and 
spontaneous bleeding, extent and magnitude of local swelling and urine output should be 
measured. If clinical compartment syndrome (marked swelling of muscles contained in a 
tight fascial compartment that might jeopardise blood supply) is suspected, intra-
compartmental pressure should be monitored. Assessing the level of consciousness of 
patients with neurotoxic envenoming can be difficult because their generalized flaccid 
paralysis makes the commonly used Glasgow Coma Scale misleading. For example, a 
patient may not be able to open their eyes, speak or obey commands, but if 
cardiorespiratory support is adequate and their paralysed upper eyelids are raised, they 
may be found to be fully conscious and able to signal ‘yes’ or ‘no’ in response to simple 
questions by flexing a finger or toe. After resuscitation and attempted species diagnosis, 
the most critical management decision is whether the patient requires antivenom. 
[H3] Antivenom. Antivenom is the only effective specific antidote for the systemic effects 
of snakebite envenoming115. Antivenom consists of concentrated immunoglobulin of 
horses, sheep or other large domesticated animals such as camels that have been 
hyperimmunised with one or more venoms over periods of months to years. Worldwide, 
most antivenom manufacturers refine the whole immunoglobulin G (IgG) extracted from 
the animals’ plasma by enzyme digestion with pepsin to produce F(ab′)2 fragments, under 
the assumption that removal of the Fc moiety from the antigen-binding (Fab) fragment 
reduces the risk of adverse reactions. Others use papain to produce smaller Fab fragments 
to improve safety and increase the speed of distribution throughout the body, but with 
the disadvantage of rapid renal clearance of the antivenom so that recurrent envenoming 
becomes a problem116. Some antivenoms consist of whole IgG molecules usually purified 
by caprylic acid precipitation115. Venom-specific antibodies can be extracted by affinity 
column purification, increasing safety but also cost. 
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Polyvalent (polyspecific) antivenoms are raised against the venoms of the most 
medically important snake species in a particular geographical area. Examples are the 
Indian antivenoms effective against the ‘big four’ national species, that is, Naja naja 
(family Elapidae), Bungarus caeruleus (family Elapidae), Daboia russelii (family Viperidae) 
and Echis carinatus (family Viperidae). By contrast, monovalent (monospecific) 
antivenoms are raised against the venom of a single species, for example, European 
ViperaTab effective for Vipera berus (family Viperidae).  
Antivenoms have proved effective against many of the lethal and damaging effects 
of venoms for more than a century. Antivenom administration can reverse anti-
haemostasis, hypotension and post-synaptic neurotoxicity and, if given early, prevent or 
limit pre-synaptic neurotoxicity, rhabdomyolysis and local tissue necrosis19,86,87,115. In the 
management of snakebites, the most important clinical decision is whether or not to give 
antivenom. Antivenoms are highly specific and, therefore, will neutralize only the venoms 
used in their production, together with those of a few related species, and so, in a 
particular case of snakebite, an appropriate antivenom must be selected, based on 
identification of the snake responsible for the envenoming. In addition, antivenoms are 
costly, often scarce, poorly distributed in areas where they are most needed and may 
require cold-chain for transport and storage117. Over the past few decades, several major 
antivenom manufacturers (such as Syntex, Behringwerke and Sanofi-Pasteur) have 
stopped production, mainly for commercial reasons, creating serious shortages in the 
countries that they previously supplied, especially in Africa118. Only a minority of patients 
bitten by a snake fulfil the criteria for antivenom use (Table 1).  
Dosage is the same for adults and children. The initial dose would ideally be based 
on clinical trial data119–123, but as these data are rarely available, the manufacturer’s 
estimate of neutralising potency, based on rodent median effective dose, is usually the 
guide. Dose is increased according to clinical estimates of severity of envenoming and is 
repeated in the face of deteriorating neurotoxic or cardiovascular signs after 1–2 hours or 
persistence of incoagulable blood after 6 hours. Administration is always intravenous, 
over 10–60 minutes. Patients must be closely observed for early anaphylactic and 
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pyrogenic reactions especially during the first 2 hours after starting antivenom treatment. 
The incidence and severity of these dose-related early adverse antivenom reactions can 
be reduced by prophylactic adrenaline administration124. If reactions do occur, they should 
be treated at the earliest sign (often itching and appearance of urticarial plaques, 
restlessness, nausea, tachycardia or tachypnoea) with adrenaline by intramuscular 
injection19,86,87,119–123.  
[H3] Additional supportive treatment. Organ and system failures caused by envenoming 
must be detected and treated (Table 2). Supraglottal or endotracheal intubation and 
assisted ventilation either manually or by a ventilator is vital in cases of bulbar and 
respiratory paralysis87. Especially in victims of species with predominantly postsynaptic 
neurotoxins such as cobras (Naja; family Elapidae), death adders (Acanthophis; family 
Elapidae) and some coral snakes (Micrurus; family Elapidae), acetylcholinesterase 
inhibitors such as neostigmine, given with atropine, may improve neuro-muscular 
transmission at least temporarily, but they are no substitute for antivenom111,125. Short-
acting acetylcholinesterase inhibitors (for example, edrophonium) or the ice pack test 
(whereby an ice pack is applied to one upper eyelid in a patient with bilateral ptosis; the 
ice lowers the local temperature and inhibits endogenous acetylcholinesterase) may be 
used to predict response to endogenous cholinesterase inhibition126. Hypotension and 
shock persisting after antivenom treatment is treated with cautious fluid volume repletion 
and pressor drugs such as dopamine19,20. If acute kidney injury progresses despite 
conservative management, renal replacement therapy is needed.  
A tetanus toxoid booster should be given in all cases, but prophylactic antibiotics 
are not justified127. However, if the wound has been incised or there are signs of tissue 
necrosis, wound infection or local abscess formation, a broad spectrum antibiotic should 
be given. Surgical debridement (removal of necrotic tissue) and skin grafting may be 
needed in some cases, and some gangrenous digits or limbs might require amputation. 
Painful, tender, tensely swollen, cold, cyanosed and apparently pulseless snake-bitten 
limbs often appear to fulfill criteria for compartment syndrome (for example, anterior 
tibial compartment), tempting surgeons to undertake fasciotomy (surgical procedure to 
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improve circulation by incising fascial compartments). Fasciotomy is rarely justified as 
intracompartmental pressure usually remains within normal limits, and fasciotomy in 
patients whose anti-haemostasis has not been corrected by adequate doses of antivenom, 
has proved catastrophic. Unnecessary fasciotomy prolongs hospital stay and contributes 
to long-term morbidity128.  
Rehabilitation is a rare luxury for snakebite victims but is essential for helping to 
restore function to the bitten limb, especially in children and agricultural workers, and to 
ameliorate the chronic physical handicap that blights the lives of many snakebite 
survivors.  
 
[H2] Hospital discharge and follow-up 
No snakebite victim should be discharged back to the same environment where 
the bite occurred without receiving practical advice, preferably in the form of a printed 
leaflet, about reducing the risk of further bites. At follow-up, patients should be checked 
for late antivenom-related serum sickness 5–15 days after treatment, and chronic physical 
and psychological sequelae of envenoming13,26. Persisting sequelae after snakebite are 
common, and include tissue loss, amputations, contractures, arthrodesis (fusion fixation 
of a joint), septic arthritis, hypertrophic and keloid scars, tendon damage, complications of 
fasciotomies, chronic skin ulcers and osteomyelitis leading to malignant Marjolin 
ulcers2,19,24,25,78,82,129. Visible and functional defects may lead to social stigmatization. 
Acute kidney injury may lead to chronic renal failure and panhypopituitarism associated 
with Russell’s viper (family Viperidae) envenoming to arrested puberty, amenorrhoea and 
infertility. Persisting neurotoxic effects include mydriasis (pupil dilatation) and loss of 
olfaction. Cerebral haemorrhages or thromboses may result in chronic neurological 
deficits, and severe presynaptic neurotoxicity to increased risk of developing late 
paralysis. Many survivors of snakebite complain of chronic or recurrent symptoms in the 
bitten limb and attribute a wide variety of physical and mental problems to that 
frightening and traumatic life event. 
25 
 
 
 
[H1] Quality of life 
Snakebite envenomings occur mostly in impoverished settings11, affecting 
underserved rural populations that, quite often, lack the appropriate resources to 
confront this neglected disease. Snakebite alters the lives of victims, but also families and 
communities because this disease largely affects people devoted to agricultural or 
pastoralist activities whose economic performance, and that of their dependents, relies on 
their good health. The death or incapacitation of someone responsible for the basic 
economic support of his or her family can devastate the socioeconomic sustainability and 
interpersonal stability of many people. Moreover, where medical treatment and especially 
antivenom is not provided free of charge, the economic cost of snakebite can be 
catastrophic — creating debt, forcing asset liquidation, and driving families further into 
the cycle of poverty130,131.  
Although many snake bites are fatal, far more leave behind victims who experience 
horrifically debilitating disfigurement and long-term disability. Without timely access to 
health systems with adequate resources and capacity the consequences of a snakebite 
envenoming may include various types of sequelae2,7,129,132,133. Where health systems 
falter, affected people as well as their families and communities must deal with these 
consequences on their own often with severe consequences, often expanding the toll of a 
single snakebite envenoming.  
This disease also exerts a heavy psychological impact, a phenomenon that has not 
received attention in medical research until recently26,134. The lack of effective diagnosis 
and treatment, and poor follow-up of affected people, even when they are treated in 
health facilities, often results in psychological consequences that remain untreated, thus 
affecting patients and their families in ways that go beyond the biomedical aspects of the 
disease26,134.  
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Rolling back the impact of snakebite envenoming on quality of life requires 
concerted and coordinated efforts spanning entire health systems. Snakebite envenoming 
is a ‘tool-ready’ disease, in the sense that effective therapy (that is, antivenom) exists, and 
other cross-cutting interventions are available to strengthen health systems, empower 
communities and encourage policy change. Implementing an effective action plan to 
control snakebite envenoming will lead to a situation where snakebite victims are treated 
rapidly with safe, effective antivenoms by trained health staff, followed up with ancillary 
treatment, together with psychological, social and economic support after hospital 
discharge. Public and private organizations, as well as community-based groups, should 
follow up and help people affected by sequelae of snakebites.  
 
[H1] Outlook 
[H2] Diagnosis 
  Deciding on when to start antivenom treatment can be difficult, particularly for 
inexperienced physicians, as signs of envenoming and their time of onset vary by snake 
genus, the amount of venom injected, the site of injection and the age and health of the 
victim. In addition, current clinical guidelines recommend withholding antivenom 
administration until symptoms of systemic envenoming are detected in snakebite victims. 
Rapid, affordable, point-of-care (bedside) diagnostic kits providing physicians in rural 
hospitals with information enabling earlier detection of envenoming and identification of 
the biting species are urgently needed, to enable earlier treatment with antivenom and 
anticipate likely clinical course and need for supportive therapy (for example, ventilation).  
An experimental lateral flow assay has been developed to identify envenoming by 
two Indian snakes; the assay uses antivenom to detect circulating venom proteins135. The 
near-ubiquitous delivery of PLA2s into the circulation of snakebite victims has been 
suggested as a marker to detect systemic envenoming136. A PCR-based approach has also 
been reported as a possible diagnostic tool for detecting venom DNA in and around the 
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bite site, but may be less useful for detecting circulating venom as a marker of systemic 
envenoming105.  
 
[H2] Management of systemic effects  
Antivenom has been the primary treatment of systemic snake envenoming for over 
a century. Whilst life-saving, antivenoms still have therapeutic limitations137,138. 
Conventional antivenom has limited efficacy against some effects of envenoming, such as 
local tissue damage, and, when treatment is delayed, presynaptic neurotoxicity. In 
addition, only 10–15% of IgG in a vial of antivenom is specific to venom proteins, because 
the animals used for antivenom manufacture already have mature immune systems, and 
hyper-immunisation with venom is unable to engender higher venom-specific IgG titres. 
Finally, the greater the phylogenetic disparity between the snakes whose venoms are used 
for immunisation, the greater the number of IgG specificities generated in the venom-
immunised animals. This means that the proportion of total IgG targeting the venom of 
any one snake is small, and consequently more vials are needed to achieve clinical cure. 
This creates a therapeutic paradox because each extra vial of antivenom increases both 
the risk of potentially severe antivenom-induced adverse effects and treatment cost. Thus, 
highly efficient, polyspecific antivenoms are needed, without compromising safety and 
affordability.  
 The rapidly increasing availability of snake venom proteomes and venom gland 
transcriptomes40 have provided essential information on venom protein composition and 
inferred function of the proteins. Together with DNA sequence information, this allows 
guided development of IgGs that target only the most toxic venom proteins. One 
approach is to analyse transcriptome data of each toxin group expressed in snake venom 
(of several snake families) to identify antigenic sequence motifs (epitopes) with the 
greatest cross-species and cross-genera sequence conservation. These motifs are 
manipulated to construct a synthetic epitope string designed to generate multiple distinct 
toxin group-specific IgGs capable of neutralizing that the entire toxin group, irrespective of 
the snake species139–141. The intent is to pool all the toxin group-specific IgGs to create a 
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polyspecific antivenom. To address the dose–efficacy challenge, the current intent is to 
isolate B cells from epitope string-immunized mice, and extract, screen and manipulate 
the IgG-encoding genes to prepare monoclonal antibodies to produce an antivenom 
consisting only of IgG capable of polyspecifically neutralising the toxins present in the 
venoms of a defined group of snakes. Humanizing these monoclonal antibodies also offers 
substantial safety advantages over the current antivenoms142.  
Another toxin-specific recombinant antivenom approach is based on screening 
bespoke high-density toxin-specific microarrays to identify the most medically-important 
venom toxin epitopes bound by clinically-effective antivenoms143. This toxin-focused 
approach aligned with the production of human or humanized IgGs (or fractions thereof, 
for example, single-chain variable fragments) using new biotechnology production 
processes may yield antivenoms at a cost similar to conventional antivenoms in the 
future144, but with a much-improved dose-efficacy. International collaborative efforts are 
underway in these research and development topics.  
Chemical inhibitor research is also being promoted142 as an overlooked but 
potentially source of drugs to treat snakebites. For example, a recent drug repurposing 
study identified a potent, broad-spectrum inhibitor of the nearly-ubiquitous group of 
venom PLA2s
145. Other efforts have been directed at the synthesis of nanoparticles which 
could sequester and neutralize venom toxins146. If successful, the chemical outputs of 
these approaches will likely have substantial cost and logistic advantages.  
A pharmacological study reported that an ointment containing a nitric oxide donor, 
which impedes the intrinsic lymphatic pump, delays ingress of venom proteins into the 
systemic circulation and improved survival of venom-injected rats147. This first aid-focused 
application is likely to be effective in predominantly neurotoxic venoms, but needs to be 
excluded for envenoming by those snakes that cause local tissue destruction. 
 
[H2] Management of local effects 
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No medicinal treatment of the local tissue-destructive effects of envenoming 
exists. Antivenom, unless it is administered very soon after the bite, is largely ineffective in 
preventing the rapidly manifested destruction of tissues by venom. Chemical inhibitors 
have potential as a treatment for venom-induced local tissue destruction owing to their 
low-cost, thermostability and rapid tissue-distribution dynamics. Small peptidomimetic 
matrix metalloproteinase inhibitors have shown exciting, repurposed, ability to neutralize 
SVMP-induced haemorrhage and dermonecrosis148. It is not inconceivable that combining 
inhibitors of SVMPs and PLA2s
145,146,148,149 may produce an affordable, rapid, polyspecific, 
and effective treatment of venom-induced tissue damage. 
Other groups are pursuing a recombinant approach using single-domain VHH 
antibody fragments, based upon the demonstration that an experimental VHH antivenom 
(prepared from the heavy chain-only IgG3 fraction of a venom-immunised dromedary 
camel) proved the most dose-effective antivenom137 to neutralize various toxic effects of 
the West African saw-scaled viper (Echis ocellatus). The small size, thermostability and 
toxin-specificity of camelid VHH promote them as exciting therapeutic candidates for 
preventing the tissue necrotic effects of envenoming for saw-scaled vipers and other 
snake venoms150,151.  
[H2] Treatment availability and accessibility  
There is a current crisis in antivenom provision in various regions, particularly sub-
Saharan Africa and parts of Asia10,138,152. The market failure of two of the most effective 
polyspecific antivenoms manufactured for Africa in the past118,138,153 underscores the fact 
that the commercial constraints associated with marketing non-subsidised conventional 
antivenoms of high cost but limited demand can result in important, life-threatening 
therapeutic gaps. It also reinforces the need to incorporate commercial realities into the 
design of innovative approaches to generate antivenoms with improved polyspecific 
efficacy, safety and affordability137,138. The research and development tasks discussed 
above need to be complemented by research and innovation in the public health realm 
that aim to improve the availability and accessibility of antivenoms, which demands 
research in subjects such as health economics, provision of health services, and other 
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social science-related topics. The long-term goal is to develop knowledge-based policies 
ensuring that people suffering snakebite envenomings receive safe and effective 
antivenoms in a timely fashion. New treatments should be affordable and available to 
invariably remote, impoverished snakebite victims138,152. In addition, innovative treatment 
and diagnostic research needs to be complemented with equally important research on 
ways to ensure affected communities can better access effective healthcare, and indeed 
upon affordable and appropriate means by which they can reduce their likelihood of being 
bitten. 
[H2] Venoms as a source of therapy  
Some of the targets of toxins are also dysregulated in a number of human diseases, 
such as thrombotic disorders, vascular pathologies, neurodegenerative diseases and 
inflammatory conditions. The study of venom toxins is of growing interest for the 
pharmacological and biotechnological communities, as venoms are increasingly 
recognized as a rich source for lead compounds that can drive the development of 
biotechnological tools and novel biotherapeutics154. Determining the molecular landscape 
of snake venoms represents the necessary first step towards these basic and applied 
goals.  
[H2] Global efforts to reduce impact 
For decades, a major barrier to effectively reducing the worldwide impact of 
snakebite envenoming has been the lack of inclusion of this disease on the global public 
health agenda. The absence of appropriate prioritization and resourcing of control efforts 
has seen snakebite envenoming fail to receive proper attention by international and 
national health authorities, fall off research priority lists and public health agendas, and 
lose the interest of the pharmaceutical industry. However, the decision of the WHO in 
June 2017 to include snakebite envenoming in the category A of its list of Neglected 
Tropical Diseases is a significant step forward in the global struggle to reduce the impact 
of this pathology. This is an essential advance that is necessary to raise the profile of 
snakebite envenoming in the eyes of Member State governments, donors and other 
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stakeholders, and to empower WHO to provide the leadership needed to coordinate a 
global control programme. WHO is the only organization with the political, operational 
and policy reach to drive an integrated global strategy involving multiple actors and a 
multidisciplinary approach, and this is clearly demonstrated by the success in combating 
other neglected tropical diseases in the five years since the London Declaration on 
neglected tropical diseases was enacted to support the WHO’s 2020 Roadmap. 
Inclusion of snakebite envenoming in the neglected tropical disease category will 
focus attention on concentrated efforts to control snakebite through an integrated and 
intensified disease management strategy incorporating several key elements, ranging 
from prevention, to improved primary treatment, rehabilitation and investment in 
research that can unlock new diagnostic and therapeutic pathways, or enhance 
surveillance and resource deployment (Box 4).  
The tasks included in Box 4 are by no means an exhaustive list of all the potential 
interventions available to immediately bring the burden of snakebite envenoming under 
effective control, but it exemplifies the key approaches that will drive the process. 
Broadening the current focus which revolves around improving treatment with 
antivenoms, measuring burden and assessing the consequences to take in a more holistic 
strategy that begins with community engagement, empowerment and education and 
spans all stages of treatment, reporting, therapeutic and diagnostic translational research, 
policy, training and research is essential. 
This integrated plan for controlling snakebite envenoming requires international 
cooperation, through a multitiered roadmap coordinated by WHO, involving many 
stakeholders: the scientific and technological research community; antivenom 
manufacturers and developers; health regulatory agencies; public health authorities at 
national, regional and global levels, and health professional organizations; international 
health foundations and advocacy groups, such as the Global Snakebite Initiative10, Health 
Action International, and others; and organizations of the civil society in countries of high 
incidence of snakebites. Realizing such as comprehensive strategy requires considerable 
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resources, and it is incumbent on United Nation Member States, donor organizations, 
snakebite experts and other actors to wholeheartedly support the leadership of WHO as it 
moves forward to implement effective control programmes and projects. 
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Box 1 | Technologies to analyse snake venom composition. 
First-generation venom proteomics (venomics) relied on reversed-phase high-
performance liquid chromatography separation and quantification of venom components 
followed by in-gel digestion of the protein bands corresponding to the chromatographic 
peaks. Protein bands were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, de novo tandem mass spectrometry sequencing of the peptides (usually 
produced by trypsin digestion) and database searching by Basic Local Alignment Search 
Tool (BLAST) analysis155. An experienced researcher typically completes this bottom-up 
analysis of a venom composed of 35 chromatographic fractions and 60-70 electrophoretic 
bands in 6-8 weeks. The bottleneck of this technique is the quality of the tandem mass 
spectrometry fragmentation spectra and the presence in the databases of a sequence 
homologous to the de novo derived amino acid sequence tag for the digested peptide 
ions. Peptide-centric approaches provide incomplete sequence coverage, and in the 
absence of a species-specific venom gland transcriptome, only provide information on 
which known protein families are present in the venom without distinguishing between 
different proteoforms (different molecular forms of a protein) or toxin isoforms (proteins 
encoded by closely related genes).  
Top-down mass spectrometry using high-resolution ion-trapping mass spectrometry in 
conjunction with comprehensible species-specific venom gland database matching156,157 
has the potential to overcome this shortcoming158,159. The top-down mass spectrometry 
configuration enables label-free relative quantification of the different protein species in 
line with their identification. However, mass spectrometry is not inherently quantitative 
because of differences in the ionization efficiency and/or detectability of the different 
components in a given sample. This analytical limitation has sparked the development of 
methods to determine absolute abundance of proteins in samples. Inductive coupled 
plasma mass spectrometry with online 34S isotope dilution analysis for the absolute 
quantitative analysis has been recently successfully applied to quantify the toxins of the 
Mozambique spitting cobra, Naja mossambica160.   
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Box 2. Toxic activities of main protein families in snake venom  
- Phospholipases A2: local and systemic myotoxicity, pain, damage to lymphatic vessels, 
oedema, neurotoxicity, nephrotoxicity and haemolysis 
- Snake venom metalloproteinases: haemorrhage, myonecrosis, extracellular matrix 
degradation, blistering, pain, oedema and cardiovascular shock, nephrotoxicity and 
coagulopathy  
- Hyaluronidases: extracellular matrix degradation 
- Three-finger toxins: cytotoxicity, necrosis and neurotoxicity 
- Dendrotoxins: neurotoxicity 
- Snake venom serine proteinases: coagulopathy, oedema and hypotension 
- Vasoactive peptides (for example, bradykinin-potentiating peptides): hypotension 
- Disintegrins: inhibition of platelet aggregation 
- C-type lectin-like proteins: inhibition or promotion of platelet aggregation and 
thrombocytopenia  
- Cysteine-rich secretory proteins: smooth muscle paralysis  
- Small basic myotoxic peptides: muscle contracture 
- Natriuretic peptides: hypotension 
- Sarafotoxins: cardiotoxicity 
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Box 3 | Initial clinical history from a snakebite victim.  
The following five brief questions have proved helpful for rapid assessment of snakebite 
victims.  
 Where were you bitten? Examine puncture marks, swelling, inflammation, 
bruising, persistent bleeding and evidence of pre-hospital traditional treatment at 
the site of the bite.  
 When were you bitten? Note that if the bite or sting was very recent, there may 
not have been time for signs of envenoming to develop. 
 What were you doing when you were bitten? Note that the circumstances of the 
bite might be diagnostic. 
 Where is the snake that bit you or what did it look like? If it was killed but was left 
behind, send someone to bring it, in whatever condition. Ask if a photo of the 
snake was taken.  
 How are you feeling now? Check whether any symptoms of envenoming have 
developed.   
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Box 4 | Recommendations for an integrated global strategy to confront snakebite 
envenoming8,138  
 Actively prevent contact and implement educational programmes that detail safe 
methods for carrying out chores or work that pose a high risk of encountering snakes. 
For example, when collecting firewood, picking up piles of raked leaves, harvesting 
crops or hunting, appropriate footwear should be worn and a torch or flashlight 
should be used to illuminate the path at night. Risk during sleeping can be minimized 
by snake-proofing dwellings and using protective (mosquito) bed-nets or raised 
sleeping platforms. 
 Establish effective, safe and affordable first aid that delays the evolution of clinical 
illness and improve transport such that victims of envenoming reach health care 
facilities for diagnosis and treatment as quickly as possible.  
 Train health professionals to implement standard treatment protocols and 
algorithms, and provide diagnostic tools to strengthen health systems and improve 
medical management of snakebite victims. 
 Develop a robust system for hospital and community-level surveillance of snakebite 
envenoming, including mandatory reporting of snake-bite victims seeking treatment, 
notifications of deaths and active detection of cases through community surveys and 
outreach programmes.  
 Establish standard definitions and measurements to facilitate the accurate collection 
and comparability of data.  
 Improve access and distribution of medicines, especially of safe, effective and 
affordable antivenoms by implementing programmes that reduce prices through 
collective bulk purchasing by consortia (governments, non-governmental 
organizations and aid donors).  
 Collaborate with the WHO Essential Medicines and Health Products department to 
improve manufacturing and quality control systems of antivenoms, which will enable 
optimization of the production pipeline.  
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 Strengthen health systems to improve the treatment of snakebite envenoming in 
health facilities from admission through to discharge and follow-up. Follow-up is 
especially important in patients with local tissue injury and disability.  
 Invest in the improvement of existing antivenom treatments and the development of 
innovative future treatments. 
 Collaborate with the WHO Neglected Tropical Diseases department to implement a 
wide range of interventions in the control, prevention and treatment of snakebite 
envenoming. 
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Figure 1. Venomous snakes. A | Schematic illustration of the venom system in a snake of 
the family Viperidae (viperids). Venom is synthesized and stored in a specialized gland. 
When a bite occurs, venom is expelled through the action of a compressor muscle that 
surrounds the venom gland, and is delivered by a duct to the fangs through which it is 
injected in the tissues of the victim. Snake species responsible for a highest mortality 
owing to snakebite envenoming are Echis ocellatus (carpet viper; family Viperidae; part b) 
and Bitis arietans (puff adder; family Viperidae; part c) in Africa, Naja naja (cobra; family 
Elapidae; part d), Bungarus caeruleus (common krait; family Elapidae; part e), Daboia 
russelii (Western Russell’s viper; family Viperidae; part f) in Asia, Bothrops atrox (common 
lancehead; family Viperidae; part g) and Bothrops asper (terciopelo; family Viperidae; part 
h) in the Americas and Oxyuranus scutellatus (Papuan taipan; family Elapidae; part i) in 
Oceania. Many other snake species are also capable of inducing life-threatening 
envenomings. Photos b–h by David A. Warrell, and photo i by David J. Williams (used with 
permission). [Note to copy editor: we have iLTPs for these images from David Warrell; please 
insert the appropriate credit line as per style.] 
Figure 2. Geographical distribution of the estimated number of snakebite envenomings 
and deaths. Data shown constitute a rough approximation of the estimated range of 
envenomings and deaths given that, in many countries, reliable information on snakebite 
morbidity and mortality are lacking, resulting in underreported data of this neglected 
tropical condition. The highest impact of snakebite envenomings occurs in Asia, sub-
Saharan Africa, Latin America and parts of Oceania. Based on estimates from5,12.  
  
Figure 3. Toxin levels in venom of Viperidae and Elapidae. The graph highlights the 
protein levels (% of the total venom proteome) and the distinct distribution of the most 
abundant toxin families in venoms of snake species from the families Viperidae 
(subfamilies Viperinae and Crotalinae) and Elapidae (subfamilies Elapinae and 
Hydrophiinae). Bars are colour-coded according to the most relevant biological activities 
of the corresponding toxin family36,40. Colour gradients indicate concentration 
dependency of the biological effect (same colour) or different effects (multiple colours; 
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that is, some toxins may exert one effect at low doses and another effect at high doses). 
The crystallographic or NMR structures of some members of each protein family are also 
shown. SVMP, snake venom metalloproteinases (Protein Data Bank (PDB) accession 3DSL 
for class PIII and PDB accession 1ND1 for class PI are shown); PLA2, phospholipases A2 
(PDB accession 1TGM for the monomer and PDB accession 3R0L for the dimer); SVSP, 
snake venom serine proteinases (PDB accession 1OP0); 3FTx, three-finger toxins (PDB 
accession 1IJC); DTx, dendrotoxins (PDB accession 1DTX); CTL, C-type lectin-like proteins 
(PDB accession 1IXX); CRISP, cysteine-rich secretory proteins (PDB accession 3MZ8); LAO, 
L-amino acid oxidases (PDB accession 2IID); Myo, low molecular mass myotoxins (PDB 
accession 4GV5). More information on the crystal structures shown and their source can 
be found in Supplementary file 2.  
Figure 4. Immunoaffinity capturing antivenomics protocol. Whole venom is applied to an 
immunoaffinity column packed with antivenom antibodies that are immobilized onto 
Sepharose beads. After eluting the non-retained venom components, the 
immunocaptured proteins are eluted. Comparison of the reversed-phase high-
performance liquid chromatographs of the components of whole venom, the fraction 
recovered from the affinity antivenom column (immunoretained fraction) and the non-
immunocaptured venom fraction (non-immunoretained fraction) can provide qualitative 
and quantitative information on the set of toxins bearing antivenom-recognized epitopes 
and those toxins exhibiting poor immunoreactivity.  
 
Figure 5. Action of snake venom toxins on different body systems. Venoms exert a wide 
spectrum of toxic activities in the body, and the predominant deleterious actions depend 
on venom composition. Elapid venoms, and some viperid venoms, induce neuromuscular 
paralysis. Most viperid venoms, and some elapid venoms, inflict prominent local tissue 
damage. Viperidae venoms cause systemic haemorrhage, which, together with increased 
vascular permeability, can lead to cardiovascular shock. Viperid and some elapid and 
colubroid venoms act at various levels of the coagulation cascade and on platelets, 
thereby affecting haemostasis. Some venoms cause generalized muscle breakdown (that 
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is, rhabdomyolysis). Acute kidney injury often develops in envenomings, owing to a 
multifactorial pathogenesis.  
Figure 6. Clinical effects of snake venoms. A | Swelling and blistering following a bite on the 
dorsum of the foot by a jararaca (Bothrops jararaca, family Viperidae) in Brazil. B | Swelling, 
blistering and gangrene of the hand, which required amputation, and extensive ecchymoses 
(discoloration of the skin owing to bleeding under the skin) following a bite of the Malayan pit-
viper (Calloselasma rhodostoma, family Viperidae) in Thailand. C | Bleeding gums, a cardinal sign 
of failure of haemostasis, in a patient bitten by a saw-scaled viper (Echis ocellatus, family 
Viperidae) in Nigeria. D | Bilateral conjunctival oedema (chemosis), indicating a generalized 
increase in capillary permeability, following a bite of Eastern Russell’s viper (Daboia siamensis, 
family Viperidae) in Myanmar. E | Bilateral ptosis (paralysis of both upper eyelids) and F | external 
ophthalmoplegia (paralysis of the eye muscles; the patient cannot look to the right), in patients 
bitten by Papuan taipans (Oxyuranus scutellatus, family Elapidae) in Papua New Guinea. G | 
Extensive necrosis of skin and sub-cutaneous tissue following a bite on the elbow by a black-
necked spitting cobra (Naja nigricollis, family Elapidae) in Nigeria. All images courtsey David A. 
Warrell. [Note to copy editor: we have iLTPs for these images from David Warrell; please insert 
the appropriate credit line as per style.] 
 
 
 
 
  
45 
 
 
Table 1. Criteria for antivenom treatment  
Clinical criterion  Clinical evidence  Additional treatment 
Shock with or without hypovolaemia 
 
 Low or falling blood pressure (with 
postural drop) 
 Increasing pulse rate 
 Prostrated or collapsed, cold, pale or 
peripherally cyanosed 
If clinically hypovolaemic, administer 
volume repletion and/or pressor drugs* 
Spontaneous systemic bleeding (at sites 
distant from the bite) 
 
 Bleeding of the gums, nose, 
gastrointestinal tract and/or 
urogenital tract 
 Stroke 
If massive or threatened (for example, in 
case of imminent surgery, child birth), 
administer fresh frozen plasma and/or 
other blood products* 
Incoagulable blood  
 
 Persistent bleeding from trauma sites 
 Positive 20WBCT 
 Altered laboratory blood coagulation 
profile  
If massive or threatened (for example, 
pre-delivery in pregnant women or before 
surgery), administer fresh frozen plasma 
and/or other blood products* 
Neurotoxicity 
 
 Bilateral ptosis 
 External ophthalmoplegia 
 Descending paralysis 
 Restore and secure airway (consider 
endotracheal intubation and assisted 
ventilation) 
 Trial of anticholinesterase or ‘ice-pack 
test’‡ 
Black urine  
 
 Macroscopic or microscopic evidence 
of haemoglobin or myoglobin in the 
urine (urine reagent strip testing) 
 Exclude haematuria  
 Restore fluid homeostasis 
 Alkalinize urine  
High risk of actute kidney injury  Oliguria/anuria 
 Rising plasma creatinine and urea  
(especially after bites by high risk 
species) 
Fluid challenge, conservative treatment or 
renal replacement  
Extensive local swelling or high risk of 
tissue necrosis 
Rapidly-progressive local swelling 
(especially bites on digits) 
 
 Monitor intra-compartment pressure 
 Administer antibiotics*  
Treatment with specific antivenom is indicated if one or more of the following criteria are fulfilled. *See Table 2. ‡ Application of an ice 
pack to one upper eyelid in a patient with bilateral ptosis; the ice lowers the local temperature and inhibits endogenous 
acetylcholinesterase; if positive, anticholinesterase can be administered. 20WBCT, 20 minute whole blood clotting test. 
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Table 2 | Approved drugs for supportive care of snakebite victims in addition to antivenom  
Drug or treatment Indication  Comment  
Adrenaline   Prevention and treatment of early 
anaphylactic antivenom reactions  
 Treatment of early autopharmacological 
anaphylactic reactions due to envenoming or 
acquired venom hypersensitivity 
 Prophylactic: subcutaneous treatment with a 
low dose before antivenom treatment. 
 Therapeutic: intramuscular injection.  
Analgesics (for example, paracetamol or 
opioids)  
Routine analgesia   Pain is an underestimated symptom; most 
snake bites are painful, some are agonizing.  
 Aspirin or NSAIDs should not be given 
because of bleeding risks. 
Antibiotics  Bite wounds that are necrotic or that have 
been tampered with 
 Clinically-obvious wound infection (for 
example, abscess), distinguished from 
inflammatory effects of envenoming 
 Prophylactic antibiotics are not indicated 
unless the wound is necrotic or has been 
tampered with.  
 The choice of antibiotic is guided by bacterial 
culture result or, if wound is necrotic, 
immediate broad spectrum cover to include 
Clostridium sp. and other anaerobic bacteria. 
Acethylcholinesterases inhibitors (for 
example, neostigmine) after atropine to 
block muscarinic effects  
 
 To prolong biological half-life of 
acethylcholine at peripheral neuro-muscular 
junctions.  
 For neurotoxic envenoming, especially by 
species with post-synaptic toxins 
Administered after positive result of test dose of 
short-acting edrophonium (a reversible 
acetylcholinesterase inhibitor) or positive ice-pack 
test* 
Antihistamine H1 blocker 
(for example, chlorphenamine) 
 Early anaphylactic reactions (after adrenaline) 
to antivenom (intravenous administration) 
 Mild late serum-sickness-type antivenom 
reactions (oral or parenteral administration) 
Ineffective for prophylaxis or for severe 
anaphylaxis 
Blood products (for example, fresh 
frozen plasma or cryoprecipitates) 
 Accelerate restoration of haemostasis in case 
of imminent surgery, child birth or severe 
bleeding 
 Conservative treatment of antihaemostatic 
disorders when no specific antivenom is 
available 
Unless venom procoagulants are neutralized with 
specific antivenom, administered clotting factors 
carry the risk of promoting thrombus-formation 
with potentially-fatal consequences 
Corticosteroids  Severe late serum-sickness (oral prednislolne) 
 Suspected or confirmed acute pituitary or 
adrenal failure (intravenous hydrocortisone) 
 Should not be used routinely for snake bites 
and have no role in treating early anaphylactic 
antivenom reactions.  
 Do not reduce the risk of recurrent 
anaphylaxis 
Pressor drugs agents (for example, 
noradrenaline, vasopressin and 
dopamine) 
 Low or falling blood pressure despite fluid 
volume replacement and specific antivenom 
administration 
 Severe anaphylaxis refractory to adrenaline 
and fluid volume repletion 
Preferable to excessive fluid replacement, which 
may precipitate volume-overload pulmonary 
oedema 
Tetanus toxoid To boost immunity against tetanus toxins in all 
cases 
 Also reassuring for non-envenomed patients.  
 Use anti-tetanus serum for neglected necrotic 
wounds in un-immunised patients 
*Application of an ice pack to one upper eyelid in a patient with bilateral ptosis; the ice lowers the local temperature and inhibits endogenous 
acetylcholinesterase; if positive, anticholinesterase can be administered. 
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